Summary
DexCom Inc. (DXCM) presented a mixed financial performance in its Q3 2013 10-Q filing. While product revenues saw a significant increase of $21.4 million to $42.5 million for the quarter compared to the prior year, driven by the G4 PLATINUM system, the company continues to operate at a loss, with an accumulated deficit of $472.8 million as of September 30, 2013. This indicates ongoing investment in research and development and commercialization efforts. Despite the ongoing losses, the company's cash position remained adequate, with $47.6 million in cash, cash equivalents, and short-term marketable securities, which management believes is sufficient to meet obligations through at least September 30, 2014. The company is actively advancing its product pipeline, with submissions for pediatric indications for the G4 PLATINUM system in the U.S. and expanded indications for professional use. Furthermore, the development of the 'DexCom Share' system for remote monitoring is progressing. However, significant risks remain, including reliance on third-party reimbursement, potential delays in regulatory approvals, intense competition, and ongoing patent litigation with Abbott.
Financial Highlights
47 data points| Revenue | $42.90M |
| Cost of Revenue | $15.30M |
| Gross Profit | $27.60M |
| R&D Expenses | $11.80M |
| SG&A Expenses | $21.60M |
| Operating Expenses | $33.40M |
| Operating Income | -$5.80M |
| Interest Expense | $200K |
| Net Income | -$6.00M |
| Shares Outstanding (Basic) | 285.60M |
| Shares Outstanding (Diluted) | 285.60M |
Key Highlights
- 1Product revenues for the three months ended September 30, 2013, increased by $21.4 million to $42.5 million, driven by higher sales volume of G4 PLATINUM systems and disposable sensors.
- 2Product gross profit for the quarter significantly increased by $20.0 million to $27.7 million, due to increased revenue, a favorable sales mix of the higher-margin G4 PLATINUM system, and improved manufacturing absorption.
- 3Research and development expenses increased by $1.5 million to $11.8 million for the quarter, primarily due to increased share-based compensation and salaries, reflecting continued investment in product innovation.
- 4Selling, General, and Administrative (SG&A) expenses rose by $6.2 million to $21.6 million for the quarter, driven by higher costs to support revenue growth and product commercialization, including increased salaries and sales commissions.
- 5The company reported an accumulated deficit of $472.8 million as of September 30, 2013, underscoring its position as an early-stage commercialization company with ongoing investments.
- 6Cash, cash equivalents, and short-term marketable securities totaled $47.6 million, which management anticipates will be sufficient to fund operations through at least September 30, 2014.
- 7DexCom submitted PMA supplements to the FDA for a pediatric indication for the G4 PLATINUM system in the U.S. and for an expanded indication for professional use during Q3 2013.